Johnson & Johnson's Q3 2015 earnings call revealed solid underlying growth despite currency headwinds, with operational sales increasing and adjusted EPS exceeding estimates. The company raised its EPS guidance and announced a $10 billion share repurchase program, signaling confidence in its financial position. Management's optimistic tone and strategies to accelerate growth in key segments suggest a positive short-term outlook for the stock.

[1]